CONSOLIDATED BALANCE SHEETS

	March 31,		December 31,
ASSETS	2007		2006
	(unaudited)
CURRENT ASSETS
Cash and cash equivalents	$	4,836,656	$	5,335,282
Accounts receivable		131,106		37,495
Inventories		69,860		19,658
Investments in marketable securities		1,634,084		2,060,875
Prepaid income taxes		49,487		38,687
Income tax receivable		750,532		710,013
Prepaid expenses, deposits, and other current assets		472,959		246,776

Total current assets		7,944,684		8,448,786

PROPERTY AND EQUIPMENT, NET		214,054		207,696

OTHER ASSETS
Intangible assets, net		364,764		376,922
Assets transferred under contractual arrangements		1,420,996		1,420,996
Total other assets		1,785,760		1,797,918

TOTAL ASSETS	$	9,944,498	$	10,454,400

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts payable	$	296,366	$	174,289
Accrued employee compensation		170,128		242,497
Other accrued expenses		160,900		150,978
Income taxes payable		45,962		45,962
Deferred tax liability		546,610		669,520
Deferred revenue		6,288		4,099

Total current liabilities		1,226,254		1,287,345

LONG TERM LIABILITIES
Deferred revenue		10,558		9,126
Liabilities transferred under contractual arrangements		1,420,996		1,042,493
Total long term liabilities		1,431,554		1,051,619

TOTAL LIABILITIES		2,657,808		2,338,964

COMMITMENTS (Note 7)

STOCKHOLDERS' EQUITY
Common stock, $.01 par value; 20,000,000 shares authorized;
2,065,425 shares issued and outstanding		20,654		20,654
Additional paid-in capital		5,459,398		5,347,641
Accumulated other comprehensive income		1,082,459		1,384,876
Retained earnings		724,179		1,362,265

Total stockholders' equity		7,286,690		8,115,436

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	9,944,498	$	10,454,400

The accompanying notes are an integral part of these consolidated financial statements

-3-

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended
	March 31,
	2007			2006

REVENUE:
PCT Products, services, other	$	37,943		$	53,414
Grant revenue		93,678			-
Total revenue		131,621			53,414

COSTS AND EXPENSES:
Cost of PCT products and services		31,654			51,546
Research and development		461,532			258,819
Selling and marketing		256,530			67,379
General and administrative		481,082			689,626
Total operating costs and expenses		1,230,798			1,067,370

Operating loss		(1,099,177	)		(1,013,956	)

OTHER INCOME (EXPENSE):
Realized gain on securities available for sale		727,473			517,938
Other operating, net		(378,503	)		-
Interest income		71,602			108,506
Total other income		420,572			626,444

Loss before income taxes		(678,605	)		(387,512	)
Income tax benefit		40,519			77,478

Net loss		(638,086	)		(310,034	)

Net loss per share - basic and diluted	$	(0.31	)	$	(0.13	)

Weighted average number of shares used to calculate net loss per share - basic and diluted		2,065,425			2,424,189

The accompanying notes are an integral part of these consolidated financial statements

-4-

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED )

	For the Three Months Ended
	March 31,
Other Comprehensive Loss	2007			2006

Net loss	$	(638,086	)	$	(310,034	)

Holding gain		302,146			438,354

Reclassification of unrealized gain to realized gain on securities during the period		(727,473	)		(517,938	)

Unrealized loss on marketable securities		(425,327	)		(79,584	)
Income tax benefit related to items
other comprehensive loss		122,910			16,998

Total other comprehensive loss, net of taxes		(302,417	)		(62,586	)
Comprehensive loss	$	(940,503	)	$	(372,620	)

The accompanying notes are an integral part of these consolidated financial statements

-5-

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Three Months Ended
	March 31,
	2007			2006
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(638,086	)	$	(310,034	)

Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization		35,478			33,843
Non-cash, stock-based, compensation expense		111,757			203,456
Loss recognized from Source Scientific, LLC		378,503			-
Realized gain on sale of marketable securities		(727,473	)		(517,938	)

Changes in operating assets and liabilities:
Accounts receivable		(93,611	)		12,621
Inventories		(50,202	)		6,749
Income tax receivable		(40,519	)		244,645
Prepaid income taxes		(10,800	)		(70,000	)
Prepaid expenses, deposits and other current assets		(226,183	)		(5,818	)
Accounts payable		122,077			64,144
Accrued employee compensation		(72,369	)		157,211
Other accrued expenses		9,922			62,807
Deferred revenue		3,621			-
Income taxes payable		-			20,491
Deferred tax liability		-			(219,949	)
Net cash used in operating activities		(1,197,885	)		(317,772	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for additions to property and equipment		(29,679	)		(2,155	)
Proceeds from sale of marketable securities		728,938			518,463
Net cash provided by investing activities		699,259			516,308

CASH FLOW FROM DISCONTINUED OPERATIONS:
Cash flows from investing activities		-			1,116,819
Net cash provided by discontinued operations		-			1,116,819

CHANGE IN CASH AND CASH EQUIVALENTS:		(498,626	)		1,315,355
Cash and cash equivalents, beginning of period		5,335,282			6,416,772
Cash and cash equivalents, end of period	$	4,836,656		$	7,732,127

SUPPLEMENTAL INFORMATION:
Income Taxes Paid	$	10,800		$	71,504

The accompanying notes are an integral part of these consolidated financial statements

-6-

PRESSURE BIOSCIENCES, INC., AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2007

1)	Organization and Business Activities

Pressure BioSciences, Inc. (“PBI”) is an early-stage company focused on the development and commercialization of a novel, enabling, platform technology called Pressure Cycling Technology (“PCT”). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

2)	Interim Financial Reporting

The accompanying unaudited consolidated financial statements of Pressure BioSciences, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2007 are not necessarily indicative of the results that may be expected for the year ending December 31, 2007. For further information, refer to the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-KSB, (the “Form 10-KSB”) for the fiscal year ended December 31, 2006.

3)	Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiaries, PBI Biotech Research Laboratories, Inc., PBI Source Scientific, Inc., and PBI BioSeq, Inc.

Use of Estimates

To prepare our consolidated financial statements in conformity with generally accepted accounting principles, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.

Revenue Recognition

We recognize revenue in accordance with the Securities and Exchange Commission’s (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition ("SAB 104"). Revenue is recognized when realized or earned when all the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed; the seller’s price to the buyer is fixed or determinable; and collectibility is reasonably assured.

Our current instrument, the Barocycler NEP3229 requires a basic level of instrumentation expertise to set-up for initial operation. In order to support a favorable first experience for our customers, we send a technical representative to the customer site to “commission” every NEP3229 that we sell. The “commissioning” process includes uncrating and setting up the instrument and delivering an introductory user training course. Product revenue related to current Barocycler instrumentation is generally recognized upon the “commissioning” of our instrumentation at the customer location. Product revenue related to disposable PULSE Tubes is recorded upon shipment through a common carrier.

-7-

PRESSURE BIOSCIENCES, INC., AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2007

In accordance with the Financial Accounting Standards Board (“FASB”) Statement of Financial Accounting Standards (“SFAS”) No. 13, “Accounting for Leases”, we account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our Consolidated Statements of Operations. We pay all maintenance costs associated with the instrument during the term of the leases.

Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award.

Revenue from extended service contracts is recorded over the life of the contracts.

Cash and Cash Equivalents

Our policy is to invest available cash in short-term, investment grade, interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair market value, and are classified as cash equivalents.

Computation of Loss per Share

Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, stock options are considered common stock equivalents in periods in which they have a dilutive effect. Stock options that are anti-dilutive are excluded from this calculation.

Potentially dilutive securities having a net effect of 139,972 shares were excluded from the calculation for the three months ended March 31, 2007. Potentially dilutive securities having a net effect of 177,879 shares were excluded from the calculation for the three months ended March 31, 2006.

Accounting for Stock-Based Compensation

On January 1, 2006, we adopted SFAS No. 123 (revised 2004), “Share-Based Payment”, or SFAS 123R, and its related implementation guidance as promulgated by both the Financial Accounting Standards Board (the “FASB”), and the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 107, or SAB 107, associated with the accounting for stock-based compensation arrangements of our employees and directors. These pronouncements require that equity-based compensation cost be measured at the grant date (based upon an estimate of the fair value of the compensation granted) and recorded to expense over the requisite service period, which generally is the vesting period.

We estimate the fair value of equity-based compensation utilizing the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, expected volatility of our stock price over the expected term, expected risk-free interest rate over the expected option term, expected dividend yield rate over the expected option term, and an estimate of expected forfeiture rates, and is subject to various assumptions. We believe this valuation methodology is appropriate for estimating the fair value of stock options granted to employees and directors which are subject to SFAS 123R requirements. These amounts are estimates and thus may not be reflective of actual future results, nor amounts ultimately realized by recipients of these grants. These amounts, and the amounts applicable to future quarters, are also subject to future quarterly adjustments based upon a variety of factors. The following table summarizes the assumptions we have utilized for grants of stock options from which we incurred compensation expense during the three months ended March 31, 2007 and March 31, 2006:

Assumptions	Outside Board Members		CEO and other Officers & Employees
Expected Life		5.0		6.0
Expected Volatility		74.6% - 77.9%		88.2% - 92.5%
Risk-Free Interest Rate		4.94%		4.94%
Expected Dividend Yield		0.0%		0.0%

-8-

We developed the above referenced assumptions based on the following rationale. We utilized the simplified method provided by SAB No. 107 to develop our estimate of expected term of the stock options granted. Under this method, stock options granted to outside board members are estimated to have an expected term of 5 years and stock options granted to our CEO and all other officers and employees are estimated to have an expected term of 6 years. All stock options granted have a 10 year contractual life. The stock options granted to outside directors vest immediately and the stock options granted to the CEO and all other officers and employees vest annually, on an equal basis over three years. SAB 107 provides a simplified approach to developing the estimate of expected term based on the average of the midpoint of the vesting period and the contractual life. The expected volatility is assumed to approximate the historical volatility that was observed during the corresponding expected term for each sub-group of option recipients. The risk-free interest rate is a weighted average approximation based on the U.S. Treasury yields in effect at the time of the grants. We used a dividend yield of zero for the calculation because we have never paid cash dividends and we have no intention to begin paying dividends in the foreseeable future. While we believe these estimates are reasonable, the compensation expense recorded would increase if the assumed expected term was increased or a higher expected volatility was used.

We recognized stock-based compensation expense of $111,757 for the three months ended March 31, 2007 and $203,456 for the three months ended March 31, 2006. The following table summarizes the effect of this stock-based compensation expense within our Consolidated Statement of Operations for both periods:

	For the Three Months Ended
	March 31,
	2007		2006
Cost of PCT products and services	$	2,620	$	2,094
Research and development		49,494		22,475
Selling and marketing		15,995		7,888
General and administrative		43,648		170,999
Total stock-based compensation expense	$	111,757	$	203,456

The provisions of SFAS 123R require that we make an estimate of our forfeiture rate and adjust the expense that we recognize to reflect the estimated number of stock options that will go unexercised. We estimate that our forfeiture rate will approximate 5% for the foreseeable future. As our workforce expands and our business matures we will continue to monitor this rate and consider adjusting our estimate if we feel it is appropriate to do so. The stock option expense recognized for the three months ended March 31, 2007 reflects our estimated forfeiture rate of 5%.

As of March 31, 2007, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $952,715.

Accounting for Income Taxes

Effective January 1, 2007, we adopted the provisions of FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes - an Interpretation of FASB Statement No. 109” (FIN 48). This interpretation clarifies the accounting for uncertainty in income taxes by prescribing a minimum recognition threshold for a tax position taken or expected to be taken in a tax return that is required to be met before being recognized in the financial statements. FIN 48 also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition.

-9-

In accordance with FIN 48, we have analyzed filing positions in all of the federal, state, and other jurisdictions where we are required to file income tax returns, as well as all open tax years in these jurisdictions. The periods subject to examination for all federal, state and other jurisdictions are the 2003 through 2005 tax years. We do not believe there are any tax positions that would increase within the next twelve-month period. Therefore, no reserves for uncertain income tax positions have been recorded and we did not record a cumulative effect adjustment related to the adoption of FIN 48.

Fair Value Measurements

In September 2006, FASB issued SFAS 157, “Fair Value Measurements”. SFAS No. 157 establishes a formal framework for measuring fair value under GAAP and expands on disclosure of fair value measurements. Although SFAS No. 157 applies to and amends the provisions of existing FASB and AICPA pronouncements, it does not, of itself, require any new fair value measurements, nor does it establish valuation standards. SFAS No. 157 applies to all other accounting pronouncements requiring or permitting fair value measurements, except for; SFAS No. 123R, share based payment and related pronouncements, the practicability exceptions to fair value determinations allowed by various other authoritative pronouncements, and AICPA Statements of Position 97-2 and 98-9 that deal with software revenue recognition. This statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years.

Effects of Prior Year Misstatements

In September 2006, the SEC staff released Staff Accounting Bulletin No. 108, "Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements," or SAB 108. SAB 108 provides for a "one-time" special transition provision for correcting certain prior year misstatements that were uncorrected as of the beginning of the fiscal year of adoption. SAB 108 permits existing public companies to initially apply its provisions either by (i) restating prior financial statements as if the dual approach had always been used or (ii) recording the cumulative effect of initially applying the dual approach as adjustments recorded to the opening balance of retained earnings. SAB 108 is effective for fiscal years ending after November 15, 2006. The adoption of SAB 108 did not have a material impact on our consolidated financial statements.

4)	Investment in Marketable Securities

As of March 31, 2007, we held 352,934 shares of common stock of Panacos Pharmaceuticals Inc. (“Panacos”), a publicly traded company listed on the NASDAQ Global Market. We account for this investment in accordance with SFAS 115 “Accounting for Certain Investments in Debt and Equity Securities” as securities available for sale. On March 31, 2007, our balance sheet reflected the fair value of our investment in Panacos to be approximately $1.6 million, based on the closing price of Panacos shares of $4.63 per share on that day. The carrying value of our investment in Panacos common stock held will change from period to period based on the closing price of the common stock of Panacos, and the number of shares we hold, as of the balance sheet date. This change in market value will be recorded by us on a quarterly basis in Comprehensive Income or Loss.

5)	Assets and Liabilities Transferred Under Contractual Arrangements

In June 2004, we transferred certain assets and liabilities of our PBI Source Scientific, Inc. subsidiary to a newly formed limited liability company known as Source Scientific, LLC. At the time of the transfer, we owned 100% of the ownership interests of Source Scientific, LLC. We subsequently sold 70% of our ownership interests of Source Scientific, LLC to Mr. Richard Henson and Mr. Bruce A. Sargeant pursuant to a purchase agreement (the “Source Scientific Agreement”). As a result of the sale of 70% of our ownership interests, Mr. Henson and Mr. Sargeant each own 35% and we own the remaining 30% of Source Scientific, LLC. Under the Source Scientific Agreement, we received notes receivable in the aggregate amount of $900,000 (the “Notes”) payable at the end of three years bearing 8% interest. The Source Scientific Agreement offers Mr. Henson and Mr. Sargeant the opportunity to purchase our 30% ownership interest in Source Scientific, LLC until May 31, 2007, at an escalating premium (10-50%) over our initial ownership value, provided that they have first paid off the Notes in their entirety.

-10-

Despite our intent to exit the laboratory instrumentation business, we may be viewed as having a continuing involvement in the business of Source Scientific, LLC. Because of this and other factors, even though the transaction is treated as a divestiture for legal purposes, we have not recognized the transaction as a divestiture for accounting purposes in accordance with SEC SAB Topic 5E, “Accounting for Divestiture of a Subsidiary or Other Business Operation”. In accordance with SAB Topic 5E, we have recorded the assets and liabilities associated with the Source Scientific, LLC operation on our consolidated balance sheet as of December 31, 2006 under the captions “Assets transferred under contractual arrangements” and “Liabilities transferred under contractual arrangements”.

During the three months ended March 31, 2007, Source Scientific, LLC reported a net loss of approximately $483,000. In accordance with SAB Topic 5E we have recorded a charge in our Consolidated Statement of Operations equal to the net book value on our Consolidated Balance Sheet of $378,503. SAB Topic 5E requires that we recognize the losses of Source Scientific, LLC to the extent such losses exceed profits in the same fiscal year. In accordance with SAB Topic 5E, we have reduced our net carrying value of our investment in Source Scientific, LLC to zero as of March 31, 2007.

During the three months ended March 31, 2007, total purchases from Source Scientific, LLC by us amounted to $100,299. During the same period in 2006, total purchases from Source Scientific, LLC by us amounted to $4,359. These purchases were for services in connection with the design and manufacture of our Barocycler instrumentation. All of our purchases from Source Scientific, LLC are negotiated as arms length transactions and paid through our normal accounts payable process. As of March 31, 2007, we had accounts payable to Source Scientific, LLC of $96,595 and deposits receivable of $344,000. As of December 31, 2006, we had accounts payable to Source Scientific, LLC of $38,605 and deposits receivable of $168,000.

6)	Inventories

Inventories represented are comprised of Barocycler instruments, PULSE Tubes, and purchased sub-components to be used in the manufacture of Barocycler instruments. As of March 31, 2007 and December 31, 2006, inventories were comprised as follows:

	March 31,		December 31,
	2007		2006
Raw materials	$	41,618	$	3,158
Finished goods		28,242		16,500
Total	$	69,860	$	19,658

7)	Commitments

Royalty Commitments

In 1998, we acquired all the remaining outstanding common stock of BioSeq, Inc., a development-stage company involved with PCT. In accordance with the provisions of a technology transfer agreement assumed in the transaction, we are obligated to pay a 5% royalty on net sales until March 2016. For purposes of the royalty calculation, net sales include the revenues related to units sold or leased as well as PULSE™ Tube revenue. The royalty obligation that we accrued for the three months ended March 31, 2007 was approximately $2,100. The royalty obligation that we accrued and paid for the same period in 2006 was $2,500.

-11-

On April 9, 2007, we extended our sub-lease agreement with Proteome Systems, Inc., pursuant to which we have agreed to lease approximately 650 sq. feet of laboratory space plus 100 sq. feet of office space from Proteome Systems in Woburn, Massachusetts. The lease period was extended through August 31, 2007 and the monthly rent was increased to $3,200 for the use of these facilities.

Operating Leases

On June 1, 2006, we entered into a lease agreement with Scheer Partners and the Maryland Economic Development Corporation, pursuant to which we have agreed to lease laboratory and office space in Rockville, Maryland. The lease period will expire on May 31, 2007, and will continue on a month-to-month basis thereafter. We will pay $2,600 per month for the use of these facilities.

Purchase Commitments

In March 2007, we executed a purchase order with Source Scientific, LLC under which we agreed to purchase 20 Barocycler NEP3229 units and nine demonstration (NEP2320) units to be used by our sales force in 2007. This purchase order is in addition to the 20 units on order under the previously placed purchase order with Source Scientific. In connection with each of these purchase orders, we submitted a deposit to Source Scientific, LLC for $200,000. In accordance with the terms of these agreements, we expect that the units will be completed during 2007. We will be billed for the complete cost of each unit as it is completed, net of the deposit we placed for each instrument. Finished goods will stay at Source Scientific, LLC for shipment directly to our customers. As of March 31, 2007, Source Scientific completed and billed us for seven units under the first purchase order.

8)	Stockholders’ Equity

Stock Options

On September 16, 2005, our stockholders approved our 2005 Equity Incentive Plan (the “Plan”) pursuant to which an aggregate of 1,000,000 shares of common stock were reserved for the issuance upon exercise of stock options or other equity awards made under the Plan. Under the Plan, our board of directors has authority to grant stock options or other equity awards to employees, officers, directors, consultants, and advisors. As of March 31, 2007, there were 790,000 stock options granted and outstanding under the 2005 Equity Incentive Plan and 210,000 shares available for future grants.

We also have 244,000 stock options outstanding under our 1999 Non-Qualified Plan and 9,500 stock options outstanding under our 1994 Incentive Stock Option Plan. As of March 31, 2007, there were 4,800 shares available for future grant under the 1999 Non-Qualified Plan. The 1994 Incentive Stock Option Plan has expired; therefore, there are no shares available for future grants under this plan.

The following tables summarize information concerning options outstanding and exercisable as of March 31, 2007:

	Options Outstanding						Options Exercisable
			Weighted Average						Weighted Average
Range of Exercise Prices		Number of Options		Contractual Life		Exercise Price		Number of Options		Contractual Life		Exercise Price
$2.50 - $2.70		159,000		5.4	$	2.64		159,000		5.4	$	2.64
2.71 - 3.08		343,000		7.4		2.96		209,000		6.9		2.98
3.09 - 3.97		414,500		9.1		3.70		65,630		8.4		3.70
3.98 - 4.25		127,000		8.6		4.05		127,000		8.6		8.63

$2.50 - $4.25		1,043,500		7.9		3.34		560,630		7.0		3.21

-12-